HomeCompareCHRO vs BTI

CHRO vs BTI: Dividend Comparison 2026

CHRO yields 148.15% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHRO wins by $23.42M in total portfolio value
10 years
CHRO
CHRO
● Live price
148.15%
Share price
$1.35
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.46M
Annual income
$10,076,148.54
Full CHRO calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — CHRO vs BTI

📍 CHRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHROBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHRO + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHRO pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHRO
Annual income on $10K today (after 15% tax)
$12,592.59/yr
After 10yr DRIP, annual income (after tax)
$8,564,726.26/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, CHRO beats the other by $8,562,357.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHRO + BTI for your $10,000?

CHRO: 50%BTI: 50%
100% BTI50/50100% CHRO
Portfolio after 10yr
$11.75M
Annual income
$5,039,467.59/yr
Blended yield
42.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

CHRO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-1.5
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHRO buys
0
BTI buys
0
No recent congressional trades found for CHRO or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHROBTI
Forward yield148.15%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$23.46M$37.7K
Annual income after 10y$10,076,148.54$2,786.64
Total dividends collected$21.69M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: CHRO vs BTI ($10,000, DRIP)

YearCHRO PortfolioCHRO Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$25,515$14,814.81$11,299$598.92+$14.2KCHRO
2$62,628$35,326.85$12,794$703.91+$49.8KCHRO
3$148,051$81,039.20$14,518$829.07+$133.5KCHRO
4$337,457$179,042.34$16,513$978.64+$320.9KCHRO
5$742,477$381,398.70$18,827$1,157.84+$723.6KCHRO
6$1,578,712$784,260.93$21,518$1,373.12+$1.56MCHRO
7$3,247,684$1,558,462.68$24,657$1,632.46+$3.22MCHRO
8$6,471,310$2,996,288.20$28,329$1,945.74+$6.44MCHRO
9$12,504,097$5,579,794.89$32,637$2,325.33+$12.47MCHRO
10$23,455,532$10,076,148.54$37,708$2,786.64+$23.42MCHRO

CHRO vs BTI: Complete Analysis 2026

CHROStock

Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Full CHRO Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this CHRO vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHRO vs SCHDCHRO vs JEPICHRO vs OCHRO vs KOCHRO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.